The Patient Activation Measure® (PAM®) Assessment to be Incorporated into Select CMS Alternative Payment Models
Sep 17, 2019
APM Model Awardees to Utilize PAM to Measure Performance
and Strengthen Patient Support
PORTLAND, Ore. - Sept. 17, 2019 - PRLog -- Insignia Health has been awarded a contract with the Centers for Medicare and Medicaid Services (CMS) to incorporate the Patient Activation Measure® (PAM®), plus a host of integrated solutions and services, to support up to five million beneficiaries.
As authorized by the Affordable Care Act, the Center for Medicare Medicaid Innovation (CMMI) develops Alternative Payment Models (APMs) aimed at achieving better individual healthcare, improved population health, and lower costs through improvements in care delivery across the United States.
To help advance its mission, CMMI has selected the Patient Activation Measure from Insignia Health to support up to five APMs with strategies to reduce cost and improve health outcomes. Participating models will utilize PAM to measure a patient's ability to manage their health and healthcare, and to assess change over time.
Endorsed by the National Quality Forum (NQF) as a performance measure, PAM is also used to guide resource allocation and patient support based upon a patient's self-management ability or activation level. Patients with lower activation struggle with self-management and utilize significantly more care when compared to patients with higher activation, including higher rates of emergency department visits, hospital readmissions, and use of ambulatory care sensitive (ACS) services.
"We are excited to be working with CMS at the forefront of value-based innovation to achieve improved health outcomes through the gains in self-management that we know patients can achieve," said Chris Delaney, CEO of Insignia Health. "Measuring patient activation with PAM has proven to be a key vital sign backed by more than a decade of evidence showing that patients low in activation, when supported appropriately, realize the greatest gains in activation and improved health outcomes."
About Insignia Health: Insignia Health is the global provider of PAM-based solutions that strengthen the identification of prospective health risk, and guide improved resource allocation and patient support. The Patient Activation Measure® (PAM®) is a predictive powerhouse backed by over 15 years of health activation research and insight gained from supporting health systems, hospitals, insurers, life science companies and government health agencies around the world. The company's products and services help organizations better identify patients at risk for poor health outcomes and then tailor care programs and support based upon a patient's level of activation. Insignia Health is headquartered in Portland, Oregon. Visit www.insigniahealth.com to learn more.
Contact
Jim Honish
***@insigniahealth.com
Photos: (Click photo to enlarge)
Click to Contact
More News
Brazil’s family farming backbone embraces Chinese AI to reverse vital sector’s decline
The family farmers who produce the lion’s share of Brazil’s staple foods are opening their arms to cutting-edge Chinese artificial intelligence in a bid to modernise operations and secure their future. Brazil and China agreed to a five-year cooperation programme in September aimed at giving smallholders – the backbone of the Brazilian agricultural sector – an AI boost after a decade of declining employment and limited access to affordable technology. Representatives of the Brazilian Agricultural...
.jpg?itok=8k9TfMIt)
From ideas to impact
[The content of this article has been produced by our advertising partner.] The HKUST-SINO One Million Dollar Entrepreneurship Competition and Impactathon take different approaches to helping promising ideas move from early concepts to practical applications in businesses and communities. Across these initiatives, Sino aims to connect innovators with communities, universities and businesses at critical stages when feedback, practical experience and industry connections can help their ideas gain...
Some GLP-1 injections recalled due to 'lack of assurance of sterility'
Apothecary Pharma, a compounding pharmacy, voluntarily recalled 22 vials of Tirzepatide injections due to a "lack of assurance of sterility," according to the official announcement.
Teen charged with hate crime over alleged threats
The 19-year-old allegedly made threats to a family at a home in Morningside.
Why foreign companies are still betting on Hong Kong’s culinary reputation
Despite a downturn in Hong Kong’s food and beverage sector, foreign enterprises are still betting on the city as a fine-dining destination, with a South Korean hydroponic ginseng grower and a 123-year-old Japanese confectioner choosing it for their first overseas ventures. Jack Kwon, founder and CEO of Seoul-based Biofx, signed a deal with Hong Kong hydroponics firm Farm66 last Thursday to grow Korean gourmet ginseng in the city and sell it to local consumers and restaurants. The deal marks the...
Elon Musk’s $5 trillion monster: Tesla and SpaceX exploring the biggest merger in history
Elon Musk says the companies have taken preliminary steps towards sealing what would rank as the largest corporate tie-up of all time.
Mike Bush speaks to media after charges were laid against Brendan Nugent
Victorian Chief Commissioner Mike Bush said police had no intelligence on the accused, Brendan Nugent, that suggested the alleged attack on Helen Haines was imminent.
Carlos Moreno on 15-minute cities
The world-leading urbanist explains the idea which he says improves the quality of life.
ASX edges higher as big banks rise; NextDC tanks after profit warning
The Australian sharemarket wavered in early trade, with gains by the Big Four banks and consumer stocks wiped out by a plunge in tech, where NextDC lost more than 40 per cent after a profit warning.
What’s that enormous pink duck doing on the Brisbane River?
CityCats are having to dodge a 15-metre tall duck on the water next to the Brisbane Powerhouse.
Why Anthropic has a major China problem ahead of its blockbuster IPO
The growing popularity of Chinese artificial intelligence models has emerged as a key risk factor for Anthropic ahead of its blockbuster initial public offering, according to US research firm Hedgeye Risk Management. “It’s all about Chinese competition when analysing Anthropic,” said Felix Wang, managing director and global tech sector head at Hedgeye. “Many of my clients are asking the same question.” The assessment comes as Anthropic faces renewed investor jitters over whether its massive AI...
Samsung says interest in its foldables surged after Apple unveiled the iPhone Duo
Apple hasn’t even got its first foldable iPhone into everyone’s hands, but it may already be doing Samsung’s foldable business a favour.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.